Evidence map›Paper›PMID 32442310›Full record

ReviewThe Journal of clinical endocrinology and metabolism2020

Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists.

Hellas Cena, Luca Chiovato, Rossella E Nappi

2 registry-linked trialsOpen access · hybridFull text readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Journal of clinical endocrinology and metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 153 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
153citing papers in PubMed, 12 pooled it
33.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05952882 phase3unknown statusstarted 2023, after this paper: background citation

Effectiveness of the Combination Liraglutide and Metformin on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With Polycystic Ovarian Syndrome, Obesity and Infertility

Ran2023Enrolled188Registered outcomes60Posted comparisons0ConditionsInfertility, Female, Obesity, Polycystic Ovary SyndromeArmsLiraglutide + metformin, Metformin
PMID 18364705PMID 28681988PMID 19056992PMID 31229399PMID 29703793PMID 19841045PMID 31733195PMID 24362411PMID 14688154PMID 17980364PMID 18068166PMID 22767467other papers from this trial
Open the trial in the graph
NCT05702905 phase4unknown statusnot on this mapstarted 2023, after this paper: background citation

Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome: a Prospective, Randomized, Open, Controlled Study

TypeinterventionalSponsorPeking University First HospitalRan2023 to 2025Enrolled75ConditionsPCOS (Polycystic Ovary Syndrome), SemaglutideArmsMetformin Hydrochloride 500 MG, Semaglutide, 1.34 mg/mL, Semaglutide, 1.34 mg/mL and Metformin Hydrochloride 500 MG, calorie-restricted diet, physical exercise
3 · Its place in the literature

Who cites it

153 citing papers in PubMed, 12 syntheses or guidelines pooled it, 319 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Adipose Tissue Dysfunction in Polycystic Ovary Syndrome.The Journal of clinical endocrinology and metabolism · 2023
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Review
  19. Review
  20. Review

93 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Hellas CenaLaboratory of Dietetics and Clinical Nutrition, Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy.
Luca ChiovatoUnit of Internal Medicine and Endocrinology, Laboratory for Endocrine Disruptors, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy.
Rossella E NappiResearch Center for Reproductive Medicine, Gynecological Endocrinology and Menopause, IRCCS San Matteo Foundation, Pavia, Italy.
University of Pavia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextObesity is responsible for an increased risk of sub-fecundity and infertility. Obese women show poorer reproductive outcomes regardless of the mode of conception, and higher body mass index (BMI) is associated with poorer fertility prognosis. Polycystic ovary syndrome (PCOS) is one of the leading causes of infertility, and many women with PCOS are also overweight or obese. EVIDENCE ACQUISITION: The aim of the present narrative review is to describe the mechanisms responsible for the development of infertility and PCOS in women with obesity/overweight, with a focus on the emerging role of glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) as a therapeutic option for obese women with PCOS. EVIDENCE SYNTHESIS: Weight reduction represents the most significant factor affecting fertility and pregnancy outcomes. Current experimental and clinical evidence suggests the presence of an underlying pathophysiological link between obesity, GLP-1 kinetic alterations, and PCOS pathogenesis. Based on the positive results in patients affected by obesity, with or without diabetes, the administration of GLP-1 RA (mainly liraglutide) alone or in combination with metformin has been investigated in women with obesity and PCOS. Several studies demonstrated significant weight loss and testosterone reduction, with mixed results relative to improvements in insulin resistance parameters and menstrual patterns.

conclusionsThe weight loss effects of GLP-1 RA offer a unique opportunity to expand the treatment options available to PCOS patients.

Indexed as

Glucagon-Like Peptide-1 Receptor AgonistsDrug Therapy, CombinationFemaleGlucagon-Like Peptide-1 ReceptorHumansIncretinsInfertility, FemaleLiraglutideMetforminObesityPolycystic Ovary SyndromeRandomized Controlled Trials as TopicTestosteroneTreatment OutcomeWeight LossGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsIncretinsLiraglutideMetforminTestosteroneGLP-1 receptor agonistsinfertilityobesitypolycystic ovary syndrome

Identifiers

PMID32442310
PMCPMC7457958
OpenAlexW3026155818

What Socratic holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.